Revolutionizing Weight Management and Obesity Treatment
In a groundbreaking development, Lilly has unveiled the remarkable results of its clinical trial involving tirzepatide, commonly known as Mounjaro for type 2 diabetes. These findings not only showcase the extraordinary weight loss achieved by individuals without diabetes but also underscore the necessity of ongoing treatment to sustain weight loss.
Lilly Presents SURMOUNT-4 Trial Results
Louis Aronne, the director of the Weill Cornell Medicine Comprehensive Weight Control Center in New York, presented the comprehensive findings of the SURMOUNT-4 trial at the European Association for the Study of Diabetes conference in Hamburg, Germany. The study’s outcomes shed light on the significant implications that tirzepatide, like SURMOUNT-4, has on the realm of weight management and prevention. Fill out this form to see if you or a friend qualify for Continuous Glucose Monitors.
According to Aronne, the treatment of obesity has undergone a remarkable transformation in recent years, with drugs like semaglutide and tirzepatide leading the charge. The SURMOUNT-4 trial results, particularly the astounding average weight loss of 26% or more among tirzepatide users, position this drug as one of the most effective weight loss medications available, even though its current approval is limited to type 2 diabetes. Another obesity drug under investigation by Lilly, retatrutide, demonstrates even greater weight loss but is still in mid-stage clinical trials. However, these results strongly align with the anticipated FDA approval of tirzepatide for obesity treatment.
Key Insights from SURMOUNT-4 Trial
The SURMOUNT-4 trial, involving 783 participants with a BMI greater than 30, revealed the need for continuous tirzepatide usage to maintain weight loss. After a 36-week period where participants received either 10 mg or 15 mg of tirzepatide, those who continued using the drug for an additional 52 weeks lost over 21% of their body weight on average.
Furthermore, participants who remained on tirzepatide for 88 weeks experienced an additional 7% weight loss, totaling an impressive 26% on average over the entire study. In contrast, individuals on a placebo for the last 52 weeks regained nearly 15% of their body weight, resulting in a 14% overall weight gain.
Read Guide about Wegovy Dosage Guide: The Best Way For Weight Loss
The trial showcased that approximately 70% of participants using tirzepatide for the entire 88 weeks achieved a weight loss of at least 20%, with more than half losing 25% or more of their body weight. This extended usage also led to an average decrease in waist circumference of 23 cm, which is equivalent to approximately nine belt holes, signifying a significant transformation in body composition.
Cardiometabolic Benefits of Tirzepatide
In addition to the substantial weight loss, participants taking tirzepatide in SURMOUNT-4 witnessed improvements in blood pressure, cholesterol levels, fasting glucose, and fasting insulin. Surprisingly, even though the participants did not have blood sugar levels, they experienced a 0.6 percentage point reduction in A1C levels, indicating the potential for diabetes prevention.
However, it remains essential to consider the long-term use of tirzepatide and similar incretin-based therapies in obesity management. The results from the SURMOUNT-4 trial emphasize the necessity of ongoing medication to maintain weight loss.
Must Read CGMs in noncritical care hospitals optimizes glycemic control
Tirzepatide’s Path to FDA Approval
Last year, the FDA granted tirzepatide “fast-track” status for obesity and overweight treatment. Dr. Garvey anticipates its approval later this year, positioning it as a direct competitor to Novo Nordisk’s popular weight loss drug, Wegovy (semaglutide).
The SURMOUNT Clinical Trial Program
Lilly’s SURMOUNT clinical trial program has yielded promising results not only for individuals with diabetes but also for those without diabetes. The program includes several trials:
SURMOUNT-1 Trial: Demonstrated that participants achieved remarkable weight loss, with those on the highest dose of tirzepatide losing an average of 52 pounds, more than 20% of their weight. Additionally, individuals with prediabetes who took tirzepatide experienced a reversion to normal glucose levels and various health improvements.
SURMOUNT-2 Trial: Showed an average weight reduction of 15.7% at the highest tirzepatide dose, along with improvements in A1C levels, fasting blood sugars, and cardiometabolic risk factors.
SURMOUNT-3 Trial: Highlighted the significant disparity between weight loss through intensive lifestyle modifications and weight loss with tirzepatide. Participants who continued tirzepatide treatment achieved the highest weight reduction ever observed in a phase 3 clinical trial.
Also Read About Free Lifetime National Parks Pass for People with Diabetes
The Road Ahead
As the journey continues towards long-term weight loss management using second-generation weight loss drugs, researchers remain focused on exploring lower doses, intermittent therapy, and additional benefits. FDA approval of tirzepatide for weight loss offers promise, yet questions concerning the sustained effectiveness and safety of long-term use persist.
The SURMOUNT-5 trial will compare Lilly’s tirzepatide with Novo Nordisk’s semaglutide, while the SURMOUNT-MMO trial will evaluate morbidity and mortality outcomes in tirzepatide users, providing further insights into the potential of this groundbreaking medication.
